Subscribe
Notably, the product previously received fast track designation from the FDA for relapsed/refractory class III or class IV lupus nephritis.
J&J purchased the full rights to bota-vec in a 2023 deal with MeiraGTx
The therapy is intended to restore hearing and support early speech development in children with OTOF-related congenital deafness.
The medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network spoke about unmet needs in patients who receive early-line CAR T for R/R MM.
The complete response rate was 88%.
Ciltacabtagene autoleucel significantly enhances survival rates in relapsed/refractory multiple myeloma, outperforming standard treatments across various patient subgroups.
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial.
These findings could support gene therapies targeting CTG18.1 that are currently in development.
259 Prospect Plains Rd, Bldg H Monroe, NJ 08831
609-716-7777
